← Back to patent-cliff list
Pilocarpine Hydrochloride (Allergan)
Tier C — Watch / tradePilocarpine Hydrochloride (Allergan)
Allergan
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mAChRs
Brand：Vuity
Indications (approved)：口腔干燥, 假晶状体, 老视, 近视, 脉络膜新生血管化, 年龄相关性黄斑变性
Regional status
US
Withdrawn
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pilocarpine Hydrochloride (Allergan)?
Approved indications include: 口腔干燥, 假晶状体, 老视, 近视, 脉络膜新生血管化, 年龄相关性黄斑变性.
When does the Pilocarpine Hydrochloride (Allergan) patent expire?
No public expiry year is available for Pilocarpine Hydrochloride (Allergan) yet; this page updates once verified.
How do I get a quote for Pilocarpine Hydrochloride (Allergan) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28